Triprolidine hydrochloride

What it is

Triprolidine hydrochloride is a first-generation (sedating) H1-antihistamine that has been in clinical use for more than seventy years. In the United States it is sold over the counter as a single-ingredient syrup for hay fever and other upper respiratory allergies, and much more commonly as one component of night-time cold and flu liquids alongside acetaminophen and dextromethorphan, or in a tablet with pseudoephedrine. Its plasma half-life is about 4 hours, shorter than most other sedating antihistamines. In some countries it is combined with codeine phosphate as a cough syrup.

What the research says

The honest summary is that the evidence for triprolidine on its own is thin. It is an antihistamine, so it blocks H1-receptors and causes drowsiness, and it is approved over the counter for allergy symptoms, but we found no randomised placebo-controlled outcome trial of triprolidine alone for allergic rhinitis. A phase 1 study published in 2020 noted that pharmacokinetic data for older first-generation antihistamines are sparse, and a 2026 poison centre review noted that despite seventy years of use there is still no standardised guidance for managing exposures. The one placebo-controlled efficacy trial we found used it for temporary sleep disturbance, where the first-night result disappeared after adjustment for outliers and only the later nights were significant. For colds, Cochrane's verdict on antihistamines applies. Harms are the class harms of a sedating antihistamine, plus a signal that adverse effects fall disproportionately on women.

Evidence grade: Limited evidence.

How it works

Drug class: First-generation (sedating) H1-antihistamine

Triprolidine blocks histamine H1-receptors, acting as an inverse agonist at them rather than a simple blocker, and like other first-generation antihistamines it crosses into the brain, which is why it causes drowsiness as well as relieving allergy symptoms. Its label lists its purpose simply as antihistamine. (Source 1)

What it is used for

• This is the approved over-the-counter indication, carried by an FDA monograph rather than by trials we could find. We found no randomised placebo-controlled outcome trial of triprolidine alone for allergic rhinitis. A poison centre review published in 2026 observes that after seventy years of use there is still no standardised guidance even for managing exposures, and a phase 1 study notes that pharmacokinetic data for these older drugs are sparse. Evidence: unknown. (Source 2)
• One randomised placebo-controlled trial in 198 adults over three nights found that the first-night advantage of triprolidine 2.5 mg disappeared once outliers were accounted for, while nights two and three and the three-night mean were significantly better than placebo. This is a single short industry-conducted trial and is not a US approved indication. Evidence: limited. (Source 3)
• The combinations are sold over the counter but Cochrane found antihistamine monotherapy has no clinically significant effect on cold symptoms and no demonstrated effect in children, while antihistamine-containing combinations show a modest global benefit in adults at the cost of more adverse effects. Evidence: limited. (Source 4)
• Most of the published human data on triprolidine involve the pseudoephedrine combination rather than triprolidine alone. A crossover pharmacokinetic study found peak triprolidine concentrations were somewhat higher from the combination tablet than from single-agent tablets; it measured blood levels, not symptom relief. Evidence: limited. (Source 5)
• A single-arm open-label post-marketing study in 250 Indian adults reported large falls in cough severity and night-time awakening over seven days. With no control group, placebo response and natural recovery from an upper respiratory infection cannot be separated from drug effect, and the combination is not a US product. Evidence: limited. (Source 6)
• Triprolidine is given to young children for allergic rhinitis, but a 2026 Texas poison centre review states there is no standardised guidance for managing exposures in this group, and the FDA does not recommend antihistamine-containing cough and cold products under 2 years. Evidence: unknown. (Source 7)

Interactions

• Alcohol (label): Alcohol adds to the drowsiness from triprolidine. The over-the-counter label tells people to avoid alcoholic drinks while using it. Limit: A label position. No study of triprolidine plus alcohol was found; the nearest human experiment is the driving simulator trial of diphenhydramine and alcohol. (Source 2)
• Sedatives and tranquillisers (label): Added sedation. The label directs people taking sedatives or tranquillisers to ask a doctor before use. (Source 2)
• Pseudoephedrine (in the fixed combination tablet) (pharmacokinetic study): Peak triprolidine blood levels were somewhat higher from the combination tablet than from the single-agent caplets, while time to peak and half-life were the same. Whether that difference matters clinically was not tested. Limit: A phase 1 study in 24 healthy volunteers comparing different formulations; the difference may reflect the tablet rather than pseudoephedrine itself, and the abstract draws no statistical conclusion about it. (Source 5)
• Codeine (in the fixed combination syrup) (case reports): In the one observational study of the combination, the adverse reactions reported were mostly constipation and sedation, both of which either drug can cause. Limit: Single-arm open-label study with no comparator, so no interaction was actually measured. (Source 6)
• Other anticholinergic medicines (clinical trial): Triprolidine adds to total anticholinergic burden, which cohort studies associate with falls and fall-related injuries in older adults with impaired cognition. Limit: A retrospective cohort, not a trial; the closest design label on the allowed list for this evidence is an observational study. Triprolidine is not named in it. (Source 8)
• Food (theoretical): We found no food-effect study for triprolidine. The label gives no instruction about taking it with or without food. Limit: The quote shows what the label's Directions section does say; the absence of any food instruction is the point. No pharmacokinetic food study was found. (Source 2)
• Sedating supplements: valerian, melatonin, kava, St John's wort (theoretical): No human study of triprolidine with any of these exists in what we searched. The concern is additive sedation only, inferred from the fact that both triprolidine and some of these supplements are sedating. Limit: That review is about the supplements taken alone, not combined with an antihistamine, and its search ran only to 2002. It prints "I-tryptophan" where l-tryptophan is meant; quoted as printed. Treat this as theoretical. (Source 9)

Stopping it

• The over-the-counter label gives no taper and no maximum duration; its only stopping instruction is to stop and ask a doctor if new symptoms appear. (Source 2)
• A 2026 scoping review of rebound itching and hives after stopping chronic antihistamines found reports only for cetirizine and levocetirizine, and none for triprolidine or any other antihistamine. That is an absence of reports, not evidence that stopping triprolidine is uneventful. (Source 10)
• Triprolidine's elimination half-life is about 4 hours, so it leaves the body faster than most other sedating antihistamines, which is the pharmacological reason to expect little carry-over between doses. (Source 5)

What goes wrong

Adverse effects in the pharmacokinetic study fell on a markedly higher proportion of women than men, with no sex difference in drug levels to explain it. (Source 5)

• Blood level study, Very low certainty.
• Size: 24 healthy adults.
• Who: Healthy adult volunteers.
• How long: Single doses across 3 crossover periods.
• Result: Adverse effects reported in a markedly higher proportion of women than men; no significant sex differences in any measured pharmacokinetic parameter.
• Funding: Research Support, Non-U.S. Gov't; manufacturer phase 1 study.

Limit of this finding: 24 volunteers; the abstract gives no numbers or rates behind "markedly higher", so the size of the difference cannot be checked.

The safety profile of this sedating antihistamine was as expected; however, adverse effects were reported in a markedly higher proportion of women than men.

In the same study, 15 of 250 patients had adverse drug reactions, mostly constipation and sedation. (Source 6)

• Case series, Very low certainty.
• Size: 250 patients.
• Who: Indian adults with dry cough.
• How long: 7 days.
• Result: 15 patients reported 17 adverse drug reactions, all mild and non-serious, none leading to discontinuation.
• Funding: Post-marketing observational study.

Limit of this finding: Open-label with no comparator, so background rates are unknown; constipation is also an expected codeine effect.

Treatment was well tolerated, with 15 patients reporting 17 adverse drug reactions (ADRs; mostly constipation and sedation).

The over-the-counter label warns of drowsiness, of excitability particularly in children, and that alcohol, sedatives and tranquillisers increase the drowsiness. (Source 2)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Anyone taking the over-the-counter syrup.
• How long: Not applicable.
• Result: No rates given.
• Funding: Regulatory record, label effective 2026-08-10.

may cause drowsiness excitability may occur, especially in children alcohol, sedatives and tranquilizers may increase the drowsiness effect avoid alcoholic beverages use caution when driving a motor vehicle or operating machinery

Sedating first-generation antihistamines impair driving more than alcohol at roughly the legal limit, and self-rated drowsiness does not predict the impairment. (Source 11)

• Randomized trial, Moderate certainty.
• Size: 40 licensed drivers.
• Who: Licensed drivers aged 25 to 44 with seasonal allergic rhinitis.
• How long: Four single-dose periods a week apart, 1 hour of simulated driving.
• Result: Overall driving performance poorest after diphenhydramine 50 mg, worse than after alcohol at about 0.1% blood alcohol concentration.
• Funding: Research Support, Non-U.S. Gov't and Research Support, U.S. Gov't, P.H.S.; the trial compares a non-sedating competitor product.

Limit of this finding: Diphenhydramine, not triprolidine. This is class evidence; triprolidine's shorter 4-hour half-life might make next-day impairment less likely, but no trial has tested that.

After participants took diphenhydramine, driving performance was poorest, indicating that diphenhydramine had a greater impact on driving than alcohol did.

Older inpatients cared for by physicians who prescribe first-generation antihistamines more often had higher odds of delirium. (Source 12)

• Survey study, Low certainty.
• Size: 328,140 admissions, 755 physicians.
• Who: General medicine inpatients aged 65 and over, 17 Ontario hospitals, 2015-2022.
• How long: 7 years of admissions.
• Result: Adjusted OR 1.41 (95% CI 1.28-1.56) for the highest versus lowest prescribing quartile; delirium in 36.6% versus 32.3% of admissions.
• Funding: Research Support, Non-U.S. Gov't.

Limit of this finding: The study measures prescribing rates at physician level, not individual triprolidine exposure, and does not break results down by agent.

Patients admitted to physicians in the highest quartile had 41% increased odds of delirium compared to the lowest quartile (aOR: 1.41, 95% CI: 1.28-1.56).

Cumulative anticholinergic exposure is associated with incident dementia in two large cohorts, with first-generation antihistamines among the most-used classes. (Source 13)

• Cohort study, Low certainty.
• Size: 3,434 participants, 797 incident dementia cases.
• Who: Adults 65 and over, Adult Changes in Thought study, Seattle.
• How long: Mean 7.3 years follow-up.
• Result: Adjusted hazard ratio 1.54 (95% CI 1.21-1.96) above 1,095 total standardised daily doses versus non-use; dose-response trend P < .001.
• Funding: Research Support, N.I.H., Extramural and Research Support, Non-U.S. Gov't.

Limit of this finding: Observational and about anticholinergic drugs as a group; triprolidine is not named. Pharmacy dispensing data also miss over-the-counter purchases, which is how most triprolidine is obtained.

A 10-year cumulative dose-response relationship was observed for dementia and Alzheimer disease (test for trend, P < .001). For dementia, adjusted hazard ratios for cumulative anticholinergic use compared with nonuse were 0.92 (95% CI, 0.74-1.16) for TSDDs of 1 to 90; 1.19 (95% CI, 0.94-1.51) for TSDDs of 91 to 365; 1.23 (95% CI, 0.94-1.62) for TSDDs of 366 to 1095; and 1.54 (95% CI, 1.21-1.96) for TSDDs greater than 1095.

A professional body holds that first-generation antihistamines have an unfavourable risk-benefit profile and should not be first-line. (Source 14)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: People with allergic rhinitis and chronic urticaria.
• How long: Not applicable.
• Result: No rates; the statement reports deaths from accidents, overdoses and sudden cardiac death with this class.
• Funding: Canadian Society of Allergy and Clinical Immunology position statement, 2019.

Limit of this finding: A position dated 2019, not a measurement, and it names diphenhydramine and hydroxyzine rather than triprolidine.

These drugs have also been found to result in death from accidents, intentional or unintentional overdoses, and sudden cardiac death.

The FDA does not recommend antihistamine-containing cough and cold products in children under 2, and safety and efficacy data under 6 are lacking. (Source 15)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Children under 6 years.
• How long: Not applicable.
• Result: No rates; the review notes serious adverse effects including death, especially with incorrect use.
• Funding: Review article; funding not stated.

Data surrounding the safety and efficacy of CCMs in patients younger than 6 years are lacking.

What the evidence supports

In the same trial, both triprolidine doses beat placebo on the objective sleep measure by night three and across the three-night mean. (Source 3)

• Randomized trial, Low certainty.
• Size: 198 adults.
• Who: Adults with temporary sleep disturbance.
• How long: 3 consecutive nights, wrist actimetry.
• Result: Adjusted sleep disturbance index lower with 2.5 mg and 5 mg versus placebo on night 3 (P = .0017 and P = .011) and for the three-night mean (P = .01 and P = .015); sleep latency improved with 2.5 mg on nights 2 and 3.
• Funding: See the preceding finding; manufacturer-affiliated authors.

Limit of this finding: A three-night trial says nothing about longer use, and the abstract reports P-values without the effect sizes behind them, so the size of the benefit cannot be judged from what is published. The higher dose was not better than the lower one.

Adjusted sleep disturbance index was significantly lower with triprolidine 2.5 and 5 mg versus placebo on night 3 (P = .0017 and P = .011, respectively) and for the mean of all 3 nights (P = .01 and P = .015, respectively).

Most young children with unintentional triprolidine exposures stayed asymptomatic, and the symptomatic ones typically had transient drowsiness. (Source 16)

• Case series, Low certainty.
• Size: 1,153 cases; 369 followed to known outcome.
• Who: Children 6 years and under, Texas Poison Center Network, 2011-2022.
• How long: Index exposure.
• Result: 302 of 369 (81.8%) remained asymptomatic; no major effects or fatalities; median reported dose did not differ significantly across outcome categories (P = 0.10)
• Funding: Not stated in the abstract.

Limit of this finding: Retrospective poison centre data, with outcome known for only 369 of 1,153 cases, so the 81.8% figure is subject to who happened to be followed up. It describes accidental exposures, not therapeutic use.

Among the 369 followed to known outcome, 302 (81.8%) remained asymptomatic. Symptomatic cases typically involved transient drowsiness that resolved with observation.

The poison centre authors concluded unintentional triprolidine exposure carries minimal risk of clinically significant toxicity in children under 6. (Source 17)

• Case series, Low certainty.
• Size: 1,153 cases.
• Who: Children under 6 years.
• How long: 2011 to 2022.
• Result: No serious clinical effects or deaths identified; the authors suggest current low-dose referral thresholds are overly conservative.
• Funding: Not stated in the abstract.

Unintentional triprolidine exposure carries a minimal risk of clinically significant toxicity in children less than 6 years old.

What the evidence does not support

In a randomised placebo-controlled trial, triprolidine's first-night advantage on an objective sleep measure disappeared after adjustment for outliers. (Source 3)

• Randomized trial, Low certainty.
• Size: 198 adults (triprolidine 2.5 mg n = 65, triprolidine 5 mg n = 66, placebo n = 67)
• Who: Adults aged 18 and over with temporary sleep disturbance, multicentre.
• How long: 3 consecutive nights.
• Result: Unadjusted night 1 sleep disturbance index lower with 2.5 mg than placebo (P = .02); after adjustment for outliers neither dose differed significantly from placebo on night 1.
• Funding: Research Support, Non-U.S. Gov't; the authors are affiliated with the product's manufacturer and two of the three also authored the company's triprolidine pharmacokinetic study.

Triprolidine 2.5 mg had a significantly lower sleep disturbance index versus placebo on night 1 (P = .02); however, when adjusted for outliers, sleep disturbance index did not significantly differ between either dose of triprolidine versus placebo on night 1.

The trial reported no excess of adverse events with triprolidine and no increase in daytime sleepiness. (Source 3)

• Randomized trial, Low certainty.
• Size: 198 adults.
• Who: Adults with temporary sleep disturbance.
• How long: 3 nights.
• Result: Adverse event frequency similar across the three groups; subjective reports of feeling more refreshed on waking with both doses, with no increase in daytime sleepiness.
• Funding: Manufacturer-affiliated authors; Research Support, Non-U.S. Gov't.

Limit of this finding: 198 people over three nights cannot detect uncommon harms, and the finding of no next-day sleepiness sits awkwardly with the class literature on next-day impairment from sedating antihistamines.

Subjective measures showed those on both doses of triprolidine felt more refreshed on awakening versus placebo for the mean of all 3 nights, with no increase in daytime sleepiness.

Pharmacokinetic data on triprolidine and other first-generation antihistamines are described by the investigators themselves as sparse despite seventy years of use. (Source 5)

• Blood level study, Low certainty.
• Size: 24 healthy adults.
• Who: Healthy adult volunteers.
• How long: Single doses, blood sampled over 24 hours, 3-way crossover.
• Result: Peak triprolidine concentration 8.4 ng/mL for the 2.5 mg single agent, 7.1 ng/mL dose-normalised for 5 mg, and 9.5 ng/mL for the triprolidine 2.5 mg plus pseudoephedrine 60 mg combination; time to peak about 1.5 hours and half-life about 4 hours in all three arms.
• Funding: Research Support, Non-U.S. Gov't; a phase 1 study of the manufacturer's own formulations.

Despite their widespread use, pharmacokinetic (PK) data are sparse for older, first-generation antihistamines.

After more than seventy years of use there is still no standardised guidance for managing triprolidine exposures in children. (Source 7)

• Case series, Low certainty.
• Size: 1,153 cases analysed, 369 followed to known outcome.
• Who: Children aged 6 and under with liquid triprolidine monotherapy exposures reported to the Texas Poison Center Network, 2011-2022.
• How long: Retrospective chart review across 12 years.
• Result: No effect estimate; the stated gap is in guidance, which the authors say drives inconsistent referral recommendations.
• Funding: Not stated in the abstract.

Triprolidine, a first-generation antihistamine, is prescribed as monotherapy for allergic rhinitis in young children. Despite over seventy years of use, there is no standardized guidance for managing exploratory exposures or therapeutic errors.

Antihistamine monotherapy has no clinically significant effect on cold symptoms and no demonstrated effect in children. (Source 4)

• Systematic review, Moderate certainty.
• Size: 18 randomised trials, 4,342 participants.
• Who: People with the common cold, no allergic component.
• How long: Up to 10 days.
• Result: No difference from placebo at 3-4 days or 6-10 days; individual symptom effects judged clinically non-significant.
• Funding: Cochrane review.

Limit of this finding: The pooled trials used various antihistamines; triprolidine is not identified separately.

Antihistamines have a limited short-term (days one and two of treatment) beneficial effect on severity of overall symptoms but not in the mid to long term.

Where the evidence is mixed

A single-arm observational study of codeine with triprolidine reported large falls in cough severity, but with no control group. (Source 6)

• Case series, Very low certainty.
• Size: 250 patients.
• Who: Indian adults with dry cough unresponsive to non-opioid antitussives, mean age 40.8 years, multicentre.
• How long: 7 days.
• Result: Cough severity fell 3.8 ± 1.8 points, frequency 2.4 ± 1.2 and night-time awakening 3.5 ± 1.8 (all p<0.001); quality of life improved 33.5 ± 19.9 points.
• Funding: Post-marketing observational study; authorship includes industry-affiliated names, funding not stated in the abstract.

Limit of this finding: Single-arm and open-label, so there is no way to separate drug effect from placebo response and natural recovery over a week; 75% of the patients had a self-limiting upper respiratory tract infection. The active codeine component is also an antitussive in its own right, so nothing here is attributable to triprolidine.

From baseline to end of study, mean±SD cough severity decreased by 3.8±1.8, frequency by 2.4±1.2, and nighttime awakening by 3.5±1.8 points (p<0.001), while QoL scores improved by 33.5±19.9 points (p<0.001). Additionally, subgroup analyses also showed significant improvements across etiologies.

Where the research disagrees

Whether triprolidine impairs the next day, given its shorter half-life

• Cravo and colleagues, reporting the manufacturer's sleep trial, Randomised placebo-controlled trial over 3 nights, 198 adults, subjective daytime sleepiness as a secondary measure: Triprolidine, a first-generation antihistamine for allergic rhinitis, has a shorter half-life and fewer persistent effects relative to other antihistamines and may be useful in the treatment of temporary sleep disturbance. (Source 3)
• Weiler and colleagues, measuring driving performance for the class, Randomised double-blind crossover simulator trial in 40 drivers, with objective driving measures, using diphenhydramine: Drowsiness ratings were not a good predictor of impairment, suggesting that drivers cannot use drowsiness to indicate when they should not drive. (Source 11)

How much

• Reference intake: Dosing is set by the package or the prescriber. As a position, the over-the-counter syrup label effective 2026-08-10 directs 2.67 mL (2.5 mg) every 4 to 6 hours for adults and children 12 and over, and 1.33 mL (1.25 mg) every 4 to 6 hours for children 6 to under 12, with children under 6 told to consult a doctor. No reference intake exists because triprolidine is a drug, not a nutrient. (Source 2)
• Upper limit: As a position, the same label caps adults and children 12 and over at 10.67 mL (10 mg) in 24 hours, and children 6 to under 12 at 5.33 mL (5 mg) in 24 hours, and states "Do not exceed recommended dosage." No tolerable upper intake level exists because this is a drug. (Source 2)
• Studied: The sleep-disturbance trial gave triprolidine 2.5 mg or 5 mg on three consecutive nights; the authors concluded 2.5 mg was the optimum of the two. (Source 3)
• Studied: The pharmacokinetic study gave single film-coated caplets of triprolidine 2.5 mg and 5 mg, and a reference tablet of triprolidine 2.5 mg with pseudoephedrine 60 mg. (Source 5)
• Studied: The dry-cough study gave codeine phosphate 10 mg with triprolidine hydrochloride 1.25 mg per 5 mL syrup, 10 mL three times daily for seven days. (Source 6)

A common belief, and what the research shows

The belief: Because triprolidine has been sold for seventy years, its benefits must be well proven.

What the research shows: Long availability is not evidence. The investigators who published the only modern pharmacokinetic study wrote that "Despite their widespread use, pharmacokinetic (PK) data are sparse for older, first-generation antihistamines." A 2026 poison centre review of 1,153 paediatric exposures observed that "Despite over seventy years of use, there is no standardized guidance for managing exploratory exposures or therapeutic errors." We found no randomised placebo-controlled outcome trial of triprolidine alone for its actual approved indication, allergic rhinitis. What exists is a three-night sleep trial, two pharmacokinetic studies, poison centre series, and trials of combinations in which triprolidine is one of several active drugs.

Questions and answers

What is it?

Triprolidine hydrochloride is a medicine, not a nutrient: a first-generation sedating antihistamine that has been in use for over seventy years. It is sold over the counter in the United States as a single-ingredient allergy syrup, in night-time cold and flu liquids with acetaminophen and dextromethorphan, and in tablets with pseudoephedrine. Its label describes its purpose in one word, antihistamine. (Source 7)

What does it do in the body?

It blocks histamine H1-receptors, which is how it reduces a runny nose, sneezing and itchy eyes in hay fever. Because first-generation antihistamines pass easily into the brain it also blocks brain histamine, which causes drowsiness and dulls concentration and memory. It reaches peak blood levels about 1.5 hours after a dose and has a half-life of about 4 hours. (Source 1)

Is it good or bad for you?

For its approved allergy use the honest answer is that nobody has published a placebo-controlled outcome trial of triprolidine alone, so there is no good measurement of benefit to weigh. The one placebo-controlled efficacy trial used it for three nights of disturbed sleep and found a benefit on nights two and three but not on night one once outliers were handled. Against that, it carries the class harms of a sedating antihistamine, and in the one modern pharmacokinetic study adverse effects fell on markedly more women than men. In accidental childhood exposures it looks benign, with most children staying asymptomatic. (Source 5)

How do you get more of it?

There is no food or behaviour that increases it. It only enters the body as a medicine: an over-the-counter syrup dosed by dropper, a night-time cold or flu liquid, or a tablet with pseudoephedrine. This describes how it is supplied, not a recommendation to take it. (Source 2)

If it is harmful, what reduces it?

There is no antidote and no established decontamination protocol. The label directs anyone who has taken too much to get medical help or call a poison control centre. The largest published series, 1,153 paediatric exposures reported to Texas poison centres, found that treatment when needed was limited to supportive care and that no major effects or deaths occurred. (Source 16)

Why might someone be low in it or missing it?

The question does not apply in the form it takes for a nutrient. Triprolidine is synthetic, is not made by the body and is not in food, so nobody is deficient in it. How much of a dose reaches the blood does vary: a review of anticholinergic drug handling reports that ageing, sex and cytochrome P450 genetics all change exposure from the same dose. (Source 18)

Which whole foods contain it or feed it?

No whole food contains triprolidine. We found no study of whether food changes its absorption, and the label gives no instruction about taking it with or without food. The only published pharmacokinetic work gave single doses to fasted healthy volunteers. (Source 5)

We searched: Europe PMC for triprolidine food effect, bioavailability and pharmacokinetic studies, and the full DailyMed Drug Facts label for the single-ingredient syrup; no food-effect study and no label food instruction found.

What happens if you do not have it?

Nothing happens from not having triprolidine, because it is not a nutrient. Stopping it after regular use has not been studied: a 2026 scoping review of rebound itching and hives after antihistamine discontinuation found reports only for cetirizine and levocetirizine and none for any other antihistamine. Its short 4-hour half-life is a reason to expect little carry-over, but that is pharmacology rather than an outcome measurement. (Source 10)

How can you test for it?

There is no clinical test for triprolidine and no reference range. It can be measured in plasma by liquid chromatography with tandem mass spectrometry, which is how its pharmacokinetics were characterised, and a method also exists for urine as part of de-addiction monitoring for related drugs, but these are research and forensic assays, not diagnostic ones. Nothing is gained by testing it in ordinary use. (Source 5)

We searched: Europe PMC for triprolidine assay, therapeutic drug monitoring and plasma concentration literature; only analytical and pharmacokinetic methods were found, with no validated clinical test or reference interval.

References

1. Indian J Dermatol. Pharmacology of antihistamines.. 2013. PMID 23723474, DOI 10.4103/0019-5154.110832. Read the source
2. DailyMed (US National Library of Medicine), SPL effective 2026-08-10. Triprolidine HCl 0.938 mg per mL oral syrup, OTC Drug Facts label: the label text of every Drug Facts content section, in document order from the SPL XML, excluding the principal display panel. The Directions table is given row by row; the colons inside its age cells are the label's own and nothing has been added between the AGE and DOSE headings. 2026. Read the source
3. J Clin Pharmacol. Efficacy of Triprolidine in the Treatment of Temporary Sleep Disturbance.. 2021. PMID 33768603, DOI 10.1002/jcph.1861. Read the source
4. Cochrane Database Syst Rev. Antihistamines for the common cold (AUTHORS' CONCLUSIONS section of the abstract). 2015. PMID 26615034, DOI 10.1002/14651858.CD009345.pub2. Read the source
5. Clin Pharmacol Drug Dev. Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers.. 2020. PMID 32133778, DOI 10.1002/cpdd.777. Read the source
6. Cureus. The Clinico-Epidemiological Profile and Effectiveness of Codeine and Triprolidine in Dry Cough Patients Not Responding to Non-Opioid-Based Antitussives: Results From a Prospective, Multicenter, Single-Arm, Open-Label Postmarketing Observational Study (RESULTS section of the abstract). 2026. PMID 41728387, DOI 10.7759/cureus.101883. Read the source
7. Clin Toxicol (Phila). A retrospective review of Texas Poison Center Network experience with pediatric triprolidine exposures (INTRODUCTION section of the abstract). 2026. PMID 41524505, DOI 10.1080/15563650.2025.2605140. Read the source
8. Drugs Aging. Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort Study (RESULTS section of the abstract). 2019. PMID 30652263, DOI 10.1007/s40266-018-00630-z. Read the source
9. J Clin Sleep Med. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence (RESULTS AND CONCLUSIONS section of the abstract). 2005. PMID 17561634, DOI 10.5664/jcsm.26314. Read the source
10. Clin Exp Allergy. Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use-A Scoping Review (RESULTS section of the abstract). 2026. PMID 41911848, DOI 10.1111/cea.70291. Read the source
11. Ann Intern Med. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator (CONCLUSIONS section of the abstract). 2000. PMID 10691585, DOI 10.7326/0003-4819-132-5-200003070-00004. Read the source
12. J Am Geriatr Soc. Association of Inpatient Prescribing of First-Generation Antihistamines With Delirium in Older Adults: A Cross-Sectional Study (RESULTS section of the abstract). 2025. PMID 41121962, DOI 10.1111/jgs.70121. Read the source
13. JAMA Intern Med. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study (RESULTS section of the abstract). 2015. PMID 25621434, DOI 10.1001/jamainternmed.2014.7663. Read the source
14. Allergy Asthma Clin Immunol. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.. 2019. PMID 31582993, DOI 10.1186/s13223-019-0375-9. Read the source
15. J Pediatr Pharmacol Ther. The Use and Safety of Cough and Cold Medications in the Pediatric Population.. 2025. PMID 39935563, DOI 10.5863/1551-6776-30.1.17. Read the source
16. Clin Toxicol (Phila). A retrospective review of Texas Poison Center Network experience with pediatric triprolidine exposures (RESULTS section of the abstract). 2026. PMID 41524505, DOI 10.1080/15563650.2025.2605140. Read the source
17. Clin Toxicol (Phila). A retrospective review of Texas Poison Center Network experience with pediatric triprolidine exposures (CONCLUSION section of the abstract). 2026. PMID 41524505, DOI 10.1080/15563650.2025.2605140. Read the source
18. Pharmacol Res Perspect. The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs.. 2021. PMID 34003603, DOI 10.1002/prp2.775. Read the source